ROBERT LANCASTER: Open Payments
NPI 1811409006 · IOWA CITY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,712 in 106 payments from 25 companies in 2025. Trend: 2023 $1,427 · 2024 $1,372 · 2025 $1,712
Food & beverage: $1,712
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $288 |
| Amgen Inc. | 23 | $248 |
| PFIZER INC. | 15 | $211 |
| AstraZeneca Pharmaceuticals LP | 7 | $173 |
| Novo Nordisk Inc | 11 | $162 |
| Lilly USA, LLC | 4 | $61 |
| Phathom Pharmaceuticals, Inc. | 2 | $58 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $46 |
| Insulet Corporation | 1 | $45 |
| GlaxoSmithKline, LLC. | 3 | $44 |
Products named: VRAYLAR, OTEZLA, FARXIGA, UBRELVY, NURTEC ODT, Wegovy, PREVNAR 20, JARDIANCE.
Industry payments across IA — which companies pay providers there.
